Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth

Two Former Prominent Pharmaceutical Executives from Pfizer and Boehringer Ingelheim to Join

SEATTLE, May 03, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the formation of a strategic advisory board comprised of prominent executives from the pharmaceutical industry. The company has named former Pfizer executive, bestselling author and thought leader, Bob Miglani, and Dr. Joseph M. Chalil, formerly an executive at Boehringer Ingelheim, to the strategic advisory board.

"Our strategic advisory board will play a key role in a number of important initiatives, including seeking partners in the pharmaceutical industry to accelerate the clinical development of our Endoxifen programs,” said Steven Quay, Ph.D., MD, President and CEO of Atossa. “Mr. Miglani and Dr. Chalil have demonstrated success with numerous partnerships and business development efforts at two of the largest and most highly-regarded companies in the pharmaceutical industry. We believe they will make valuable contributions to our strategic advisory board as we identify and execute arrangements to help bring our therapeutics to market,” continued Dr. Quay.

Bob Miglani

Bob Miglani worked at Pfizer Inc. in roles of increasing responsibility over the course of 23 years, spanning many functions including sales, marketing research, pricing and reimbursement, communications, patient advocacy, market access, partnership development, strategy and external medical affairs. Bob’s leadership helped Pfizer develop strong partnerships with organizations such as the World Medical Association and AARP. In addition, Bob served as Chief of Business Development for a disruptive startup, Applied DNA Sciences, where he helped bring in a large strategic partner to help grow the company’s business in life sciences. As a thought leader, Bob speaks to organizations globally on new and exciting technologies in healthcare, global change and embracing disruption.

Dr. Joseph Chalil

Prof. Joseph M. Chalil, MD, MBA, FACHE, is an expert in Pharmaceutical and Biotechnology Clinical Development and Medical Affairs with over 17 years’ experience in the field. Dr. Chalil is a member of Healthcare Advisory Board and an Adjunct Professor at Nova Southeastern University in Florida. He is the current Chairman of the Global Clinical Trial Network of American Association of Physicians of Indian Origin (AAPI), the second largest physician organization in the U.S., second only to AMA.

Formerly, a Physician Executive at Boehringer Ingelheim and a veteran of the U.S. Navy Medical Corps, Dr. Chalil is also board certified in healthcare management, and has been awarded Fellowship by the American College of Healthcare Executives, an international professional society of more than 40,000 healthcare executives who lead hospitals, healthcare systems and other healthcare organizations.

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 866 893-4927

Investor Relations Contact:

Scott Gordon
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560

Source: Atossa Genetics Inc.